DYNACIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYNACIN (DYNACIN).
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
| Metabolism | Minocycline is extensively metabolized in the liver via glucuronidation and by hydroxylation of the benzyl ring. Three major metabolites have been identified: 9-hydroxyminocycline, 7-hydroxyminocycline, and M-5 (a glucuronide conjugate). Minor pathways include demethylation and N-dealkylation. It is not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%). |
| Half-life | Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days. |
| Protein binding | 70-80% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 0.7-1.5 L/kg; high distribution into tissues including skin, bone, and prostate; doxycycline accumulates in macrophages and inflammatory cells. |
| Bioavailability | Oral: approximately 90-100% absorption; reduced by food (not significant clinically). |
| Onset of Action | Oral: 1-2 hours; IV: within 30 minutes; topical: variable, typically 2-6 weeks for clinical improvement in acne vulgaris. |
| Duration of Action | Oral/IV: 24 hours (once-daily dosing maintains therapeutic levels); topical: prolonged effect due to follicular retention; clinical improvement continues for weeks after cessation. |
100 mg orally twice daily or 200 mg orally once daily.
| Dosage form | CAPSULE |
| Renal impairment | No adjustment required for mild to moderate renal impairment. For severe impairment (GFR <30 mL/min), reduce dose to 100 mg once daily. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), reduce dose to 100 mg once daily. |
| Pediatric use | Children ≥12 years: 100 mg orally twice daily or 200 mg orally once daily. Children <12 years: not recommended. |
| Geriatric use | No specific dose adjustment required. Use with caution due to increased risk of adverse effects (e.g., photosensitivity, gastrointestinal intolerance). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DYNACIN (DYNACIN).
| Breastfeeding | Minocycline is excreted into human milk in low concentrations. The milk-to-plasma ratio is approximately 0.5–1.0. Because of the potential for serious adverse reactions in nursing infants, such as tooth discoloration and inhibition of bone growth, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | DYNACIN (minocycline) is classified as FDA Pregnancy Category D. Tetracyclines cross the placenta and may cause fetal harm. First trimester: No increased risk of major malformations from limited human data. Second and third trimesters: Exposure may cause permanent discoloration of deciduous teeth (yellow-gray-brown) if administered during dental development (from 4th month of gestation). Risk of reversible inhibition of fetal skeletal growth due to binding to calcium in bone. Animal studies show embryotoxicity and teratogenicity at high doses. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to minocycline, tetracyclines, or any component of the formulation.","Use during pregnancy (risk of permanent tooth discoloration and reversible bone growth inhibition in fetus).","Use in children <8 years (due to permanent tooth discoloration and bone growth inhibition; exception for conditions like anthrax).","Concomitant use with oral isotretinoin (risk of pseudotumor cerebri).","Severe hepatic impairment (relative contraindication; use with caution)."]
| Precautions | ["Hepatotoxicity: Rare but serious; monitor liver function. Cases of autoimmune hepatitis with minocycline.","Permanent tooth discoloration (avoid in children <8 years unless other drugs not likely effective or contraindicated).","Pseudotumor cerebri (intracranial hypertension): Risk with minocycline; discontinue if symptoms (headache, blurred vision, diplopia) occur.","Photosensitivity: Exaggerated sunburn risk; avoid excessive sunlight/tanning.","Superinfection (including C. difficile diarrhea).","Use in renal impairment: May accumulate; dose adjustment recommended (CrCl <80 mL/min).","Lupus-like syndrome, serum sickness-like reactions reported.","Neurologic effects: Dizziness, vertigo, ataxia (commonly occurs; caution when driving).","Bone growth inhibition (avoid in premature infants and children <8 years).","Thyroid dysfunction: Monitor thyroid function with prolonged use."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests, renal function, and blood counts during prolonged therapy. If used in pregnancy, monitor fetal development with ultrasound and consider serial growth assessments due to risk of skeletal growth retardation. Monitor for signs of hepatotoxicity or pancreatitis in the mother. |
| Fertility Effects | Minocycline may impair fertility in males and females based on animal studies. In humans, case reports suggest reversible infertility due to sperm motility impairment or menstrual irregularities. Cautious use in patients planning pregnancy. |